Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-(N-hydroxy-N‑iodophenylcarbamoyl)glutathione is a synthetic small molecule derivative of glutathione, in which the glutathione moiety is conjugated to an N-hydroxy-N‑iodophenyl carbamoyl group. It has been studied primarily as an experimental inhibitor and ligand for glyoxalase I (also known as lactoylglutathione lyase), an enzyme involved in the detoxification of methylglyoxal via the glyoxalase system. Structural studies have shown that this compound binds to human glyoxalase I, making it useful for probing enzyme mechanism and structure-function relationships[4][7]. There are no approved therapeutic indications or clinical trials reported for this compound; its use is limited to biochemical and structural research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S-(N-hydroxy-N-iodophenylcarbamoyl)glutathione.